
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is viewed positively because its core reconstructive franchise remains anchored by leading share in the U.S., Europe, and Japan, while large joints still drive roughly two-thirds of revenue and a diversified second leg spans extremities, trauma, and sports medicine. The outlook is strengthened by a broad robotic portfolio and the pulled-forward mid-2027 launch of Monogram, which surgeons described as potentially disruptive through faster procedures, fewer trays, better accuracy, and support for cementless knee adoption, with 2027 EPS estimated at $8.91 and 2027 organic growth modeled at 3.5%. Additional support comes from the commercial transition tracking well, Paragon 28 growing above recent organic rates, and margin-accretive innovation such as iodine-coated hips, all of which reinforce the company’s transformation toward improved fundamentals.
Bears say
Zimmer Biomet Holdings is exposed to a downside case driven by deferred elective procedures from COVID-related capacity constraints, which can pressure large-joint volumes and limit near-term revenue recovery. Its outlook is also weakened by slower adoption of ROSA and recently launched products such as PERSONA, where capital constraints, competition, and weaker pull-through to implants could reduce expected operating leverage and prevent OM expansion toward +30%. Additional risks include disruption from the 2022 spine/dental spin-off, pricing pressure such as China VBP, and less operating leverage than planned, which together could sustain a declining growth environment.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zimmer Biomet Hlds (ZBH) Forecast
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares